ERBB2 and cancer: This trastuzumab-conjugated oNK, designated as ACE1702, exerted in vitro and in vivo antitumor activity against cancer cells expressing HER2, suggesting that it could be used as a novel NK cell therapy against solid tumors that express HER2 on their surface (185).